DMRA
NASDAQDamora Therapeutics Inc.
$24.74-0.48 (-1.90%)
News19/Ratings2
Price$24.74-0.41 (-1.61%)
01:45 PM07:45 PM
News · 26 weeks19-64%
2025-10-262026-04-19
Mix1990d
- Insider10(53%)
- SEC Filings4(21%)
- Analyst2(11%)
- Offering1(5%)
- Leadership1(5%)
- Other1(5%)
Latest news
19 items- ANALYSTRBC Capital Mkts initiated coverage on Damora Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $40.00
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- INSIDERSEC Form 4 filed by Jarrett Jennifer4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jarrett Jennifer3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora's Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants made on March 24,
- INSIDERSEC Form 4 filed by Winslow Garrett4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Turtle Cameron4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Landsittel Michael4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Fairmount Funds Management Llc4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Cain Christopher W.4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Bruno Julianne4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Turtle Cameron3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Landsittel Michael3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- ANALYSTEvercore ISI initiated coverage on Damora Therapeutics with a new price targetEvercore ISI initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $46.00
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors. "We are excited to welcome Jen to Damora as we accel
- SECSEC Form S-8 filed by Damora Therapeutics Inc.S-8 - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) ("Damora" or the "Company") (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. "At Damora Therapeuti
- SECSEC Form 10-K filed by Damora Therapeutics Inc.10-K - Damora Therapeutics, Inc. (0001800315) (Filer)